Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
678actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-29 | actual | When the study began enrolling |
| Primary completion | 2025-03-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-31 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Melanoma
Interventions
- Biological: Nivolumab + Relatlimab
- Biological: Nivolumab + Ipilimumab
- Biological: Immunotherapy monotherapy
- Drug: BRAF/MEK inhibitors
Primary outcomes
what the primary-completion date above is the date OFDemographics
measured Baseline
Clinical characteristics: Location of metastatic sites
measured Baseline
Clinical characteristics: Lactate dehydrogenate (LDH) test results
measured Baseline
Clinical characteristics: BRAF status
measured Baseline
Clinical characteristics: Eastern Cooperative Oncology Group Performance Status (ECOG PS)
measured Baseline
Overall survival (OS)
measured Up to 3-years
Real-world progression-free survival (rwPFS)
measured Up to 3-years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed